Maze Therapeutics, Inc. (NASDAQ:MAZE)
| Market Cap | 1.42B-11.1% |
| Revenue (ttm) | 20.00M+700.0% |
| Net Income | -133.59M-10.6% |
| EPS | -2.74-62.5% |
| Shares Out | 55.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,515.554 |
| Open | 25.97 |
| Previous Close | 26.25 |
| Day's Range | 25.13 - 25.97 |
| 52-Week Range | 21.95 - 53.65 |
| Beta | 2.15 |
| Analysts | Buy |
| Price Target | 64.00(+149.95%) |
| Earnings Date | Nov 5, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MAZE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MAZE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MAZE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MAZE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MAZE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MAZE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MAZE
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $37.52M |
| IWMiShares Russell 2000 ETF | $24.33M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $9.59M |
| VXFVanguard Extended Market ETF | $8.75M |
| IWOiShares Russell 2000 Growth ETF | $7.31M |
| IBBiShares Biotechnology ETF | $6.80M |
Estimated from each fund’s disclosed top holdings × AUM
MAZE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MAZE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score